

## Anti-IL-1β (Canakinumab), Human IgG1 Antibody

rev 06/21

CATALOG NO.: A2144-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a recombinant human IgG1 kappa monoclonal antibody that is produced in murine Sp2/0-Ag14 cell line. This antibody binds to and neutralizes human IL-1β preventing association with its receptor and subsequent inflammatory signaling cascade. The antibody neither has cross-reactivity with IL-1α nor with the Interleukin 1 receptor, type I (IL1R1). The original monoclonal antibody was developed to treat rheumatoid arthritis. It received FDA approval in 2009 to treat cryopyrin-associated periodic syndromes (CAPS). Additionally, in 2016, the original antibody also received approval for the treatment of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulinemia D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), and Familial Mediterranean Fever (FMF).

ALTERNATE NAMES: IL-1, IL1F2, IL1beta, IL1-BETA, IL1B

ANTIBODY TYPE: Monoclonal

CONCENTRATION: Lot specific

HOST/ISOTYPE: Recombinant / IgG1, kappa

SOURCE: CHO cells

**IMMUNOGEN:** Human IL-1β

**PURIFICATION:** Protein A purified


FORM: Liquid


FORMULATION: In PBS, pH 7.5


SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80 °C. Avoid freeze/thaw cycles

This information is only intended as a guide. The optimal dilutions must be determined by the user







SDS-PAGE Analysis to assess purity and integrity of Anti-IL- $1\beta$  (Canakinumab), Human IgG1 Antibody

## **RELATED PRODUCTS:**

Anti-IL-6Rα (Sarilumab), Human IgG1 Antibody (A2133)
Anti-PD-1 (Spartalizumab) humanized Antibody (A2131)
Anti-IL-2R alpha (Daclizumab), Human IgG1 Antibody (A1099)
Anti-IL-2R alpha (CD25) (Basiliximab), Human IgG1 Antibody (A1098)
Anti-IL-6 receptor (Tocilizumab), Human IgG1 Antibody (A1447)

FOR RESEARCH USE ONLY! Not to be used on humans.

